{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:05:22Z","timestamp":1793124322258,"version":"4.5.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031258","name":"UCSI University","doi-asserted-by":"publisher","award":["REIG-FAS-2023\/006"],"award-info":[{"award-number":["REIG-FAS-2023\/006"]}],"id":[{"id":"10.13039\/100031258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031258","name":"UCSI University","doi-asserted-by":"publisher","award":["REIG-FAS-2024\/001"],"award-info":[{"award-number":["REIG-FAS-2024\/001"]}],"id":[{"id":"10.13039\/100031258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jncc.2025.01.007","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:34:10Z","timestamp":1745030050000},"page":"362-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Advancements in antibody-drug conjugates as cancer therapeutics"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1728-1895","authenticated-orcid":false,"given":"Jung Yin","family":"Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Phuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di Yang","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9579-943X","authenticated-orcid":false,"given":"Christophorus Manuel","family":"Heryanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Shyan","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khang Chiang","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Huen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3044-2718","authenticated-orcid":false,"given":"Allan Wee Ren","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel Lian Aun","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-8858","authenticated-orcid":false,"given":"Michelle Yee Mun","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jncc.2025.01.007_bib0001","unstructured":"World Health Organization. Cancer. Accessed February 3, 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0002","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/sj.bjc.6600309","article-title":"Anticancer drug development","volume":"86","author":"Loadman","year":"2002","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.jncc.2025.01.007_bib0003","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.jncc.2025.01.007_bib0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich\u2019s magic bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/bjc.1983.4","article-title":"Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer","volume":"47","author":"Ford","year":"1983","journal-title":"Br J Cancer"},{"issue":"5118","key":"10.1016\/j.jncc.2025.01.007_bib0007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.8327892","article-title":"Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates","volume":"261","author":"Trail","year":"1993","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: ongoing and future clinical development","volume":"29","author":"Grillo-L\u00f3pez","year":"2002","journal-title":"Semin Oncol"},{"issue":"sup1","key":"10.1016\/j.jncc.2025.01.007_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/cbt.199","article-title":"Classical chemotherapy: mechanisms, toxicities and the therapeutc window","volume":"2","author":"Malhotra","year":"2003","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"10.1016\/j.jncc.2025.01.007_bib0010","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nbt0905-1073","article-title":"Monoclonal antibody successes in the clinic","volume":"23","author":"Reichert","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"15","key":"10.1016\/j.jncc.2025.01.007_bib0011","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers15153886","article-title":"Antibody\u2013drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"issue":"11","key":"10.1016\/j.jncc.2025.01.007_bib0013","doi-asserted-by":"crossref","first-page":"10593","DOI":"10.1007\/s11033-022-07651-3","article-title":"Expression of mammalian proteins for diagnostics and therapeutics: a review","volume":"49","author":"Mark","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16841-9","article-title":"Antibody CDR amino acids underlying the functionality of antibody repertoires in recognizing diverse protein antigens","volume":"12","author":"Peng","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jncc.2025.01.007_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1357342","article-title":"Structure-guided engineering and molecular simulations to design a potent monoclonal antibody to target aP2 antigen for adaptive immune response instigation against type 2 diabetes","volume":"15","author":"Khan","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4161\/mabs.20776","article-title":"Molecular engineering of antibodies for therapeutic and diagnostic purposes","volume":"4","author":"Ducancel","year":"2012","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.jncc.2025.01.007_bib0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jncc.2025.01.007_bib0019","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-61779-974-7_13","article-title":"Humanization by CDR grafting and specificity-determining residue grafting","volume":"907","author":"Kim","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jncc.2025.01.007_bib0020","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11063","article-title":"Development of a single-chain fragment variable fused-mutant HALT-1 recombinant immunotoxin against G12V mutated KRAS colorectal cancer cells","volume":"9","author":"Teo","year":"2021","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1541-7786.MCR-21-0248","article-title":"Current advances and trends in KRAS targeted therapies for colorectal cancer","volume":"20","author":"Teo","year":"2022","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.jncc.2025.01.007_bib0022","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jmb.2009.12.046","article-title":"Engineering fully human monoclonal antibodies from murine variable regions","volume":"396","author":"Bernett","year":"2010","journal-title":"J Mol Biol"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12896-020-00628-9","article-title":"Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin","volume":"20","author":"Jiemy","year":"2020","journal-title":"BMC Biotechnol"},{"issue":"3","key":"10.1016\/j.jncc.2025.01.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/mog2.46","article-title":"Microtubule-targeting agents for cancer treatment: seven binding sites and three strategies","volume":"2","author":"Wang","year":"2023","journal-title":"MedComm \u2013 Oncology"},{"issue":"2","key":"10.1016\/j.jncc.2025.01.007_bib0027","first-page":"43","article-title":"DNA damaging agent-based antibody-drug conjugates for cancer therapy","volume":"1","author":"Fu","year":"2018","journal-title":"Antib Ther"},{"key":"10.1016\/j.jncc.2025.01.007_bib0028","doi-asserted-by":"crossref","first-page":"e6639","DOI":"10.7717\/peerj.6639","article-title":"Cytotoxic and apoptosis-inducing effects of wildtype and mutated Hydra actinoporin-like toxin 1 (HALT-1) on various cancer cell lines","volume":"7","author":"Ng","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.jncc.2025.01.007_bib0029","article-title":"Messengers from the gut: gut microbiota-derived metabolites on host regulation","volume":"13","author":"Li","year":"2022","journal-title":"Front Microbiol"},{"issue":"12","key":"10.1016\/j.jncc.2025.01.007_bib0030","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jncc.2025.01.007_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0033","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acs.bioconjchem.1c00029","article-title":"Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates","volume":"32","author":"Chuprakov","year":"2021","journal-title":"Bioconjug Chem"},{"issue":"20","key":"10.1016\/j.jncc.2025.01.007_bib0034","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0035","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid\u2013valine\u2013citrulline linkers ensure stability and efficacy of antibody\u2013drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jncc.2025.01.007_bib0036","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/acs.bioconjchem.0c00357","article-title":"Tailored linker chemistries for the efficient and selective activation of ADCs with KSPi payloads","volume":"31","author":"Lerchen","year":"2020","journal-title":"Bioconjug Chem"},{"issue":"11","key":"10.1016\/j.jncc.2025.01.007_bib0037","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1021\/acsmedchemlett.0c00325","article-title":"Chemical modification of linkers provides stable linker\u2013payloads for the generation of antibody\u2013drug conjugates","volume":"11","author":"Poudel","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"10.1016\/j.jncc.2025.01.007_bib0038","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of \u03b2-glucuronide linkers for monoclonal antibody\u2212drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug Chem"},{"issue":"9","key":"10.1016\/j.jncc.2025.01.007_bib0039","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1039\/C9SC06410A","article-title":"Sulfatase-cleavable linkers for antibody-drug conjugates","volume":"11","author":"Bargh","year":"2020","journal-title":"Chem Sci"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/srep16599","article-title":"Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis","volume":"5","author":"Zhen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jncc.2025.01.007_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1121964","article-title":"Role of LGMN in tumor development and its progression and connection with the tumor microenvironment","volume":"10","author":"Khan","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jncc.2025.01.007_bib0042","unstructured":"Vincerx Pharma NRCM. Vincerx\u2014Next-generation antibody\u2013drug conjugates with enhanced therapeutic windows. Accessed October 30, 2024. https:\/\/www.nature.com\/articles\/d43747-021-00011-3"},{"key":"10.1016\/j.jncc.2025.01.007_bib0043","unstructured":"Vincerx Pharma. Vincerx Pharma doses first patient in the phase 1 clinical trial evaluating VIP943 - Vincerx Pharma. Accessed October 30, 2024. https:\/\/investors.vincerapharma.com\/news-releases\/news-release-details\/vincerx-pharma-doses-first-patient-phase-1-clinical-trial"},{"issue":"15","key":"10.1016\/j.jncc.2025.01.007_bib0044","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2174\/1381612023394485","article-title":"Beta-glucuronidase-mediated drug release","volume":"8","author":"Graaf","year":"2002","journal-title":"Curr Pharm Des"},{"issue":"7_Supplement","key":"10.1016\/j.jncc.2025.01.007_bib0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/1538-7445.AM2023-596","article-title":"Abstract 596: development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments","volume":"83","author":"Cai","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.01.007_bib0046","unstructured":"MediLink Therapeutics. TMALIN. Accessed April 18, 2024. https:\/\/www.medilinkthera.com\/technology"},{"issue":"46","key":"10.1016\/j.jncc.2025.01.007_bib0047","doi-asserted-by":"crossref","first-page":"13635","DOI":"10.1002\/anie.201507391","article-title":"Near-IR light-mediated cleavage of antibody\u2013drug conjugates using cyanine photocages","volume":"54","author":"Nani","year":"2015","journal-title":"Angew Chem Intl Ed Engl"},{"key":"10.1016\/j.jncc.2025.01.007_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104475","article-title":"Novel antibody-drug conjugate with UV-controlled cleavage mechanism for cytotoxin release","volume":"111","author":"Li","year":"2021","journal-title":"Bioorg Chem"},{"issue":"39","key":"10.1016\/j.jncc.2025.01.007_bib0049","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1039\/C9SC03016F","article-title":"A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates","volume":"10","author":"Zang","year":"2019","journal-title":"Chem Sci"},{"issue":"9","key":"10.1016\/j.jncc.2025.01.007_bib0050","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/acschembio.2c00468","article-title":"Chemoenzymatic probes reveal peptidoglycan recognition and uptake mechanisms in Candida albicans","volume":"17","author":"Li","year":"2022","journal-title":"ACS Chem Biol"},{"issue":"43","key":"10.1016\/j.jncc.2025.01.007_bib0051","doi-asserted-by":"crossref","first-page":"17133","DOI":"10.1021\/jacs.9b05833","article-title":"Copper-triggered bioorthogonal cleavage reactions for reversible protein and cell surface modifications","volume":"141","author":"Wang","year":"2019","journal-title":"J Am Chem Soc"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0052","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/biomedicines5040064","article-title":"Site-specific antibody conjugation for ADC and beyond","volume":"5","author":"Zhou","year":"2017","journal-title":"Biomedicines"},{"issue":"19","key":"10.1016\/j.jncc.2025.01.007_bib0053","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1158\/1078-0432.CCR-10-0987","article-title":"Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2\u2013positive breast cancer","volume":"16","author":"Junutula","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"40","key":"10.1016\/j.jncc.2025.01.007_bib0054","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1073\/pnas.1211023109","article-title":"Synthesis of site-specific antibody-drug conjugates using unnatural amino acids","volume":"109","author":"Axup","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jncc.2025.01.007_bib0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/bc400490z","article-title":"Production of site-specific antibody\u2013drug conjugates using optimized non-natural amino acids in a cell-free expression system","volume":"25","author":"Zimmerman","year":"2014","journal-title":"Bioconjug Chem"},{"issue":"2","key":"10.1016\/j.jncc.2025.01.007_bib0056","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0057","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201602267","article-title":"Sortase A-generated highly potent anti-CD20-MMAE conjugates for efficient elimination of b-lineage lymphomas","volume":"13","author":"Pan","year":"2017","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0058","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/antib8040054","article-title":"Antibody-drug conjugates targeting the urokinase receptor (uPAR) as a possible treatment of aggressive breast cancer","volume":"8","author":"Harel","year":"2019","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0059","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2149057","article-title":"A glyco-engineering approach for site-specific conjugation to Fab glycans","volume":"15","author":"Jaramillo","year":"2023","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.jncc.2025.01.007_bib0060","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/acs.bioconjchem.1c00314","article-title":"One-pot conversion of free sialoglycans to functionalized glycan oxazolines and efficient synthesis of homogeneous antibody\u2013drug conjugates through site-specific chemoenzymatic glycan remodeling","volume":"32","author":"Ou","year":"2021","journal-title":"Bioconjug Chem"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0061","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"10.1016\/j.jncc.2025.01.007_bib0062","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1021\/acsmedchemlett.6b00312","article-title":"Expanding the reach of antibody\u2013drug conjugates","volume":"7","author":"Chari","year":"2016","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0063","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/ijms22041748","article-title":"In vitro and in vivo efficacy of a novel glucose\u2013methotrexate conjugate in targeted cancer treatment","volume":"22","author":"Wo\u017aniak","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0064","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-016-2058-y","article-title":"Novel c-Met inhibitor suppresses the growth of c-met-addicted gastric cancer cells","volume":"16","author":"Park","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1158\/1535-7163.MCT-12-0949","article-title":"Bcl-2\/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models","volume":"12","author":"Tan","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"12_Supplement","key":"10.1016\/j.jncc.2025.01.007_bib0066","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1538-7445.AM2022-2336","article-title":"Abstract 2336: pan-cancer analysis of NAMPT inhibitors reveals unique sensitivities to multiple NAMPT inhibitors in several cancer types","volume":"82","author":"Hong","year":"2022","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0067","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1021\/acs.bioconjchem.2c00178","article-title":"A novel NAMPT inhibitor-based antibody\u2013drug conjugate payload class for cancer therapy","volume":"33","author":"B\u00f6hnke","year":"2022","journal-title":"Bioconjug Chem"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0068","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/cbic.201200007","article-title":"The carmaphycins: new proteasome inhibitors exhibiting an \u03b1,\u03b2-epoxyketone warhead from a marine cyanobacterium","volume":"13","author":"Pereira","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.jncc.2025.01.007_bib0069","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejmech.2018.10.024","article-title":"Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents","volume":"161","author":"Almaliti","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jncc.2025.01.007_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115039","article-title":"New insights into the anticancer therapeutic potential of maytansine and its derivatives","volume":"165","author":"Zafar","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.jncc.2025.01.007_bib0071","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/1535-7163.MCT-21-0915","article-title":"Preclinical evaluation of IMGC936, a next-generation maytansinoid-based antibody\u2013drug conjugate targeting ADAM9-expressing tumors","volume":"21","author":"Scribner","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"10.1016\/j.jncc.2025.01.007_bib0072","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.3390\/molecules27248828","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy: present and future","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0073","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody\u2013PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem Biol"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0074","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3390\/cells9041019","article-title":"Targeted phototherapy for malignant pleural mesothelioma: near-infrared photoimmunotherapy targeting podoplanin","volume":"9","author":"Nishinaga","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jncc.2025.01.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10388","article-title":"Near-infrared-induced drug release from antibody\u2013drug double conjugates exerts a cytotoxic photo-bystander effect","volume":"7","author":"Takahashi","year":"2022","journal-title":"Bioeng Transl Med"},{"issue":"11","key":"10.1016\/j.jncc.2025.01.007_bib0076","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/1878-0261.12375","article-title":"Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors","volume":"12","author":"Rye","year":"2018","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2025.01.007_bib0077","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12013-014-0477-4","article-title":"Dormant cells: the original cause of tumor recurrence and metastasis","volume":"72","author":"Li","year":"2015","journal-title":"Cell Biochem Biophys"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0078","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.121.000503","article-title":"Simulating the selection of resistant cells with bystander killing and antibody coadministration in heterogeneous human epidermal growth factor receptor 2\u2013positive tumors","volume":"50","author":"Menezes","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0079","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0080","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12070","article-title":"Extracellular vesicles as modifiers of antibody-drug conjugate efficacy","volume":"10","author":"Barok","year":"2021","journal-title":"J Extracell Vesicles"},{"issue":"8","key":"10.1016\/j.jncc.2025.01.007_bib0081","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3390\/pharmaceutics15082020","article-title":"A novel dual-payload ADC for the treatment of HER2+ breast and colon cancer","volume":"15","author":"Mckertish","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jncc.2025.01.007_bib0082","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"issue":"16_Supplement","key":"10.1016\/j.jncc.2025.01.007_bib0083","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1538-7445.AM2020-2270","article-title":"Abstract 2270: RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1\/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells","volume":"80","author":"Deak","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.01.007_bib0084","series-title":"Regular and Young Investigator Award Abstracts","first-page":"A546","article-title":"521\u2005AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies","author":"Zhong","year":"2022"},{"issue":"Suppl 2","key":"10.1016\/j.jncc.2025.01.007_bib0085","first-page":"482.2","article-title":"FRI0164\u2005safety, tolerability, and functional activity of ABT-122, A Dual TNF- and IL-17A\u2013Targeted DVD-IGTM, following single-dose administration in healthy subjects","volume":"74","author":"Mansikka","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"16_Supplement","key":"10.1016\/j.jncc.2025.01.007_bib0086","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1538-7445.AM2020-528","article-title":"Abstract 528: EMB-01: an innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy","volume":"80","author":"Ren","year":"2020","journal-title":"Cancer Res"},{"issue":"02","key":"10.1016\/j.jncc.2025.01.007_bib0087","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1055\/s-0042-1749334","article-title":"Generating a bispecific antibody drug conjugate targeting PRLR and HER2 with improving the internalization","volume":"04","author":"Zong","year":"2022","journal-title":"Pharmaceutical Fronts"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2025.01.007_bib0088","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e15013","article-title":"Preclinical antitumor activity of an anti-HER2\/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor","volume":"41","author":"Zhong","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2025.01.007_bib0089","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s11912-022-01334-9","article-title":"Antibody\u2013drug conjugates in non-small cell lung cancer: emergence of a novel therapeutic class","volume":"24","author":"Marks","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"23","key":"10.1016\/j.jncc.2025.01.007_bib0091","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0092","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1535-7163.MCT-21-0009","article-title":"A biparatopic antibody\u2013drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade","volume":"20","author":"DaSilva","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.jncc.2025.01.007_bib0093","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1535-7163.MCT-22-0414","article-title":"A bispecific METxMET antibody\u2013drug conjugate with cleavable linker is processed in recycling and late endosomes","volume":"22","author":"Perez","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.jncc.2025.01.007_bib0094","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0095","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody\u2013drug conjugates: a new era of targeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discov Today"},{"issue":"19","key":"10.1016\/j.jncc.2025.01.007_bib0096","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0097","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"16","key":"10.1016\/j.jncc.2025.01.007_bib0098","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0099","article-title":"Targets of tumor microenvironment for potential drug development","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm \u2013 Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2025.01.007_bib0100","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/bloodadvances.2022008303","article-title":"Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia","volume":"7","author":"Le","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.jncc.2025.01.007_bib0101","doi-asserted-by":"crossref","first-page":"11564","DOI":"10.1182\/blood-2022-159910","article-title":"A novel antibody-drug conjugate targeting CCR7 in hematologic malignancies","volume":"140","author":"Dang","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-022-04487-3","article-title":"Exposure\u2013response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical hodgkin lymphoma and non-hodgkin lymphoma","volume":"91","author":"Toukam","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6_suppl","key":"10.1016\/j.jncc.2025.01.007_bib0103","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1200\/JCO.2022.40.6_suppl.087","article-title":"DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a subgroup analysis of a phase 1\/2 multicenter study","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2025.01.007_bib0104","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","article-title":"Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"39","author":"Jang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2025.01.007_bib0105","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2023.41.16_suppl.3027","article-title":"Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: dose expansion results","volume":"41","author":"Carneiro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0106","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0107","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer \u2014 Role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2025.01.007_bib0108","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1002\/mco2.542","article-title":"Cellular senescence in cancer: molecular mechanisms and therapeutic targets","volume":"5","author":"Jin","year":"2024","journal-title":"MedComm (2020)"},{"issue":"21","key":"10.1016\/j.jncc.2025.01.007_bib0109","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1002\/1878-0261.13312","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset","year":"2022","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2025.01.007_bib0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular senescence promotes adverse effects of chemotherapy and cancer relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0111","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/cancers12040822","article-title":"Therapy-induced senescence: an \u201cold\u201d friend becomes the enemy","volume":"12","author":"Saleh","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.jncc.2025.01.007_bib0112","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1158\/0008-5472.CAN-22-0787","article-title":"Therapy-induced senescence enhances the efficacy of HER2-targeted antibody\u2013drug conjugates in breast cancer","volume":"82","author":"Duro-S\u00e1nchez","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0113","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99852-2","article-title":"Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker","volume":"11","author":"Poblocka","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0114","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12979-020-00187-9","article-title":"Role of immune cells in the removal of deleterious senescent cells","volume":"17","author":"Kale","year":"2020","journal-title":"Immun Ageing"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0115","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.3390\/ijms24065857","article-title":"New senolysis approach via antibody\u2013drug conjugate targeting of the senescent cell marker apolipoprotein D for skin rejuvenation","volume":"24","author":"Takaya","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0116","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer \u2014 Role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"41","key":"10.1016\/j.jncc.2025.01.007_bib0117","doi-asserted-by":"crossref","first-page":"67033","DOI":"10.18632\/oncotarget.11475","article-title":"Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)","volume":"7","author":"Perez","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jncc.2025.01.007_bib0118","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.jncc.2025.01.007_bib0119","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1038\/s41388-019-0695-8","article-title":"Lysosomal trapping of palbociclib and its functional implications","volume":"38","author":"Llanos","year":"2019","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.jncc.2025.01.007_bib0120","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity","volume":"26","author":"Hafner","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0121","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4149\/neo_2011_01_35","article-title":"Epigenetic modulation of gene expression of human leukemia cell lines \u2013 induction of cell death and senescence","volume":"58","author":"Elknerova","year":"2011","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0122","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13148-018-0531-y","article-title":"Effects of novel HDAC inhibitors on urothelial carcinoma cells","volume":"10","author":"Kaletsch","year":"2018","journal-title":"Clin Epigenetics"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0123","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2010.10.016","article-title":"Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma","volume":"71","author":"Amatori","year":"2011","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0124","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","article-title":"Biomarkers of response and resistance to antiangiogenic therapy","volume":"6","author":"Jain","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2025.01.007_bib0125","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/1535-7163.MCT-15-0627","article-title":"CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma","volume":"15","author":"D\u00e4britz","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur J Cell Biol"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0127","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.01.007_bib0128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/molecules28030917","article-title":"Site-specific antibody conjugation with payloads beyond cytotoxins","volume":"28","author":"Zhou","year":"2023","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0129","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.jncc.2025.01.007_bib0130","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers15102858","article-title":"Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jncc.2025.01.007_bib0131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41419-024-06837-w","article-title":"The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies","volume":"15","author":"Yu","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jncc.2025.01.007_bib0132","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer","volume":"36","author":"Salifu","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"10.1016\/j.jncc.2025.01.007_bib0133","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody\u2013drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.jncc.2025.01.007_bib0134","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug\u2013antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody\u2013maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug Chem"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0135","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jncc.2025.01.007_bib0136","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.jncc.2025.01.007_bib0137","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0138","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.jncc.2025.01.007_bib0139","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1021\/acs.oprd.2c00227","article-title":"Payloads for antibody\u2013drug conjugates","volume":"26","author":"Goundry","year":"2022","journal-title":"Org Process Res Dev"},{"issue":"8","key":"10.1016\/j.jncc.2025.01.007_bib0140","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.apsb.2021.03.033","article-title":"Influencing factors and strategies of enhancing nanoparticles into tumors in vivo","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0141","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0142","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0143","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jncc.2025.01.007_bib0144","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jncc.2025.01.007_bib0145","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.xphs.2024.04.023","article-title":"Negative\u201d impact: the role of payload charge in the physicochemical stability of auristatin antibody\u2013drug conjugates","volume":"113","author":"Johann","year":"2024","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.jncc.2025.01.007_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113503","article-title":"Engineering CD276\/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability","volume":"42","author":"Feng","year":"2023","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.jncc.2025.01.007_bib0147","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14712598.2023.2276288","article-title":"Antibody-drug conjugates in oncology: insights into current challenges","volume":"23","author":"Al Meslamani","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jncc.2025.01.007_bib0148","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.jncc.2025.01.007_bib0149","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody\u2013drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jncc.2025.01.007_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.jncc.2025.01.007_bib0151","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005425000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005425000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:33:48Z","timestamp":1762641228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005425000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":151,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2667005425000432"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2025.01.007","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in antibody-drug conjugates as cancer therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2025.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}